Phaseline

Targets › SIGMAR1

SIGMAR1 (Sigma non-opioid intracellular receptor 1): drug programs, companies and trials

8 programs from 7 companies in 16 trials: 6 Phase 1, 5 Phase 2, 3 Phase 3, 2 Phase 4; Psychiatry, Neurology, Oncology; next expected readout Dec 2026.

Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. (UniProt, Q99720)

Open in Phaseline: the race on SIGMAR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CSPC Ouyi PharmaceuticalDextromethorphan
Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist
SIGMAR1, GRIN2APhase 3Major Depressive Disorder (MDD)Dec 2026
ZogenixFenfluramine
Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist
HTR1D, HTR2C, SIGMAR1Phase 3CDKL5 Deficiency Disorder; Dravet Syndrome (DS); Dravet Syndrome; Infantile SpasmNov 2027
UCB BIOSCIENCESfenfluramine hydrochloride
Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist
HTR1D, HTR2C, SIGMAR1Phase 3Rett SyndromeFeb 2029
ExcivaDextromethorphan (EXV-802)
Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist
SIGMAR1, GRIN2APhase 2Agitation Associated With Alzheimer's Disease Dementia; Obsessive-Compulsive Disorder; Hodgkin Lymphoma; Psychedelic Effects in Healthy Volunteers …Jan 2029
ExcivaEXV-801
Sigma-1 receptor agonist
SIGMAR1Phase 2Agitation Associated With Alzheimer's Disease DementiaJan 2029
Anavex Life SciencesANAVEX3-71
Dual SIGMAR1 receptor agonist and M1 positive allosteric modulator
SIGMAR1, CHRM1Phase 2Schizophrenia–
Pentixapharm[90Y]Y-PentixaTher
Yttrium-90 labelled sigma-1 receptor ligand for endoradiotherapy
SIGMAR1Phase 1CNS LymphomaSep 2027
Yale University(S)-[18F]FBFP
Sigma-1 receptor radiotracer
SIGMAR1Phase 1Healthy Control SubjectsMay 2028

Conditions

Agitation Associated With Alzheimer's Disease Dementia (2) Healthy Control Subjects (2) Rett Syndrome (1) Schizophrenia (1) CNS Lymphoma (1) Obsessive-Compulsive Disorder (1) Hodgkin Lymphoma (1) Psychedelic Effects in Healthy Volunteers (1) Major Depression (1) CDKL5 Deficiency Disorder (1) Dravet Syndrome (DS) (1) Dravet Syndrome (1)

Modalities

small molecule (7), protein or peptide (1)

Companies

Exciva (2) UCB BIOSCIENCES (1) Anavex Life Sciences (1) Pentixapharm (1) Yale University (1) Zogenix (1) CSPC Ouyi Pharmaceutical (1)

Related targets

HTR1D (2) HTR2C (2) GRIN2A (2) CHRM1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.